Recent FDA decisions added new options for dermatologists involved in treating patients with psoriasis, bullous pemphigoid ...

Vyne Therapeutics has given up hopes of resuming a plaque psoriasis trial for its BET inhibitor placed on hold by the FDA, ...

The dermatology market in the U.S. is at a pivotal moment of transformation, with spending poised to climb from $40.55 billion in 2023 to $70 billion by 2030. This unprecedented growth mirrors past ...

A new subgroup analysis reveals that adolescents with moderate-to-severe plaque psoriasis treated with once-daily icotrokinra ...

The additional presentation is approved for the treatment of pediatric patients aged 6 to 17 years with plaque psoriasis or ...

A new study published in the Journal of American Medical Association showed that dupilumab (Dupixent), used for treating ...

Boehringer Ingelheim’s Spevigo (spesolimab) has been recommended by the National Institute for Health and Care Excellence ...

However, this new study, led by researcher Hye Sun Gwak, reviewed data from 13 different studies and found that some of these ...